ClinicalTrials.gg
CompletedNCT01742299Updated Oct 29, 2026Results posted

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

A Phase 4 interventional study of imatinib mesylate in GIST and CML, sponsored by Novartis Pharmaceuticals. Completed at 29 sites in 11 countries. Open to participants aged 0 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Updated Oct 29, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
155
Allocation
Not applicable
Ages
0 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing imatinib in Gastrointestinal Stromal Tumors — 8 open to participants now, 9 under way, 2 of them phase 3. imatinib · Gastrointestinal Stromal Tumors.

Enrollment
7th of 50
155 · median 56
Started
2013
with 1 other
Phase 4
3 of 50
none open now
Registered
34th of 50
by date
Lead sponsor
10 of 50
Novartis Pharmaceuticals

Among the 50 studies testing imatinib in Gastrointestinal Stromal Tumors, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 4, and was the 34th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

8 of the 50 studies testing imatinib in Gastrointestinal Stromal Tumors are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 0 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing imatinib in Gastrointestinal Stromal Tumors, or all of them as a file.
02

Study summary

This Phase IV, open-label, multicenter roll-over study evaluated the long-term safety of imatinib in patients who had completed a previous Novartis-sponsored imatinib study and were considered by the investigator to continue benefiting from treatment.

Read the detailed description

There was no screening period. After providing informed consent and meeting the eligibility criteria, patients entered the study directly from their parent study. The starting imatinib dose was the same as the dose received in the parent study and could subsequently be adjusted based on the investigator's clinical judgment.

Patient evaluations were recommended every 12 weeks, with a permitted window of plus or minus 1 week. Evaluations could be conducted on site or remotely at the investigator's discretion. At each scheduled evaluation, the investigator confirmed whether the patient continued to derive clinical benefit and could remain on study treatment. Patients returned to the study center every 24 weeks, with a permitted window of plus or minus 1 week, for resupply of study medication, unless otherwise managed according to local practice.

Patients continued treatment until they no longer derived clinical benefit, developed unacceptable toxicity, withdrew consent, did not comply with the protocol, discontinued based on the investigator's judgment, died, or transferred to commercial supply in accordance with applicable country requirements.

Adverse events and serious adverse events were collected throughout the treatment period. After the last dose of study treatment, patients were followed for safety for 30 days. The study ended after all patients had completed their final protocol-required assessment.

03

Conditions studied

  • GIST and CML

Keywords

  • Glivec/Gleevec
  • Chronic Myeloid Leukemia (CML)
  • Gastrointestinal Stromal Tumors (GIST)
  • Imatinib mesylate
04

Who can participate

Ages eligible
0 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is currently enrolled in a Novartis-sponsored, Global Drug Development \& Global Medical Affairs study receiving imatinib and has fulfilled all their requirements in the parent study.
  • Patient is currently benefiting from the treatment with imatinib, as determined by the investigator.
  • Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
  • Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures.
  • Written obtained prior to enrolling in roll-over study.
  • If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.

Exclusion criteria

Exclusion Criteria:

  • Patient has been permanently discontinued from imatinib treatment in the parent study due to unacceptable toxicity, non-compliance to study procedures, withdrawal of consent or any other reason.
  • Patient has participated in a Novartis sponsored combination trial where imatinib was dispensed in combination with another study medication and patient is still receiving combination therapy.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hcG laboratory test.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during the study and for 30 days after the final dose of imatinib.

Highly effective contraception is defined as either:

  • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or total hysterectomy, bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
  • Male sterilization (at least 6 months prior to enrolling). For female patients on the study the vasectomized male partner should be the sole partner for that patient.
  • Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

If a study patient becomes pregnant or suspects they are pregnant during the study or within 30 days of the final dose of imatinib, the Investigator/Study Doctor needs to be informed immediately and ongoing study treatment with imatinib has to be stopped immediately.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    imatinib mesylate

    Patients who completed a previous Novartis-sponsored imatinib study, continued to derive clinical benefit from treatment, and entered this roll-over study to receive ongoing imatinib therapy. Treatment continued until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, non-compliance, investigator decision, death, or transition to commercial supply, as applicable.

    Drug: imatinib mesylate

Interventions

  • Imatinib was administered orally at a total daily dose ranging from 100 to 800 milligrams. The starting dose was the same as the dose received in the parent study and could subsequently be adjusted based on the investigator's clinical judgment. Imatinib was supplied as 100 milligram and 400 milligram tablets and was administered once daily or, for patients receiving 800 milligrams daily, as 400 milligrams twice daily.

    Also known as: STI571

06

What researchers measure

Primary outcomes

  1. Frequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Long-term safety was evaluated by assessing the frequency and severity of adverse events and serious adverse events occurring during the study.

    Time frame: From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)

Secondary outcomes

  1. Proportion of Participants With Clinical Benefit as Assessed by the Investigator

    Clinical benefit was assessed by the investigator at scheduled visits, and the proportion of patients who continued to derive clinical benefit from imatinib treatment was summarized throughout the study. At each assessment, the investigator confirmed whether the patient continued to have clinical benefit and could remain on treatment.

    Time frame: Up to approximately 157 months

07

Results

Posted Oct 29, 2026

Participant flow

The study was conducted globally across 11 countries: China, Finland, France, Hong Kong, Romania, Singapore, Switzerland, Thailand, Turkey, United Kingdom, and USA.

Participant flow — Overall Study
MilestoneImatinib Mesylate
Started155
Completed25
Not completed130
Withdrew: Adverse event16
Withdrew: Death23
Withdrew: Disease progression20
Withdrew: Lost to follow-up5
Withdrew: Physician decision27
Withdrew: Protocol violation1
Withdrew: Subject/guardian decision16
Withdrew: Technical problems2
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryFrequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Long-term safety was evaluated by assessing the frequency and severity of adverse events and serious adverse events occurring during the study.

Time frame:
From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)
Reported as:
Count of participants · Participants
Frequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsImatinib Mesylate
All deaths27
On treatment deaths19
Adverse Events (AEs) - all grades88
Treatment-related Adverse events - all grades47
Serious Adverse Events (SAEs) - all grades48
AEs leading to discontinuation - all grades21
AEs leading to dose adjustment/interruption - all grades50
SecondaryProportion of Participants With Clinical Benefit as Assessed by the Investigator

Clinical benefit was assessed by the investigator at scheduled visits, and the proportion of patients who continued to derive clinical benefit from imatinib treatment was summarized throughout the study. At each assessment, the investigator confirmed whether the patient continued to have clinical benefit and could remain on treatment.

Time frame:
Up to approximately 157 months
Reported as:
Count of participants · Participants
Proportion of Participants With Clinical Benefit as Assessed by the Investigator
ParticipantsImatinib Mesylate
Week 247
Week 4849
Week 728
Week 9641
Year 377
Year 474
Year 566
Year 663
Year 756
Year 850
Year 947
Year 1042
Year 1135
Year 1222
Year 1318

Adverse events

Collected over Adverse events were collected from the first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months). The median treatment exposure was 1,485 days (approximately 49 months). Deaths were collected from study entry through study completion (up to approximately 157 months). On-treatment deaths (up to 30 days after last dose) and deaths (thereafter) are reported separately.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib Mesylate (On-Treatment)19/155 (12.3%)58/155 (37.4%)53/155 (34.2%)
Imatinib Mesylate (Post-Treatment)8/136 (5.9%)——
Most frequent serious events
Showing 10 of 100
Most frequent serious events
EventImatinib Mesylate (On-Treatment)Imatinib Mesylate (Post-Treatment)
PneumoniaInfections and infestations13/155—
Hip fractureInjury, poisoning and procedural complications6/155—
AnaemiaBlood and lymphatic system disorders4/155—
Cardiac failure congestiveCardiac disorders4/155—
Urinary tract infectionInfections and infestations4/155—
Second primary malignancyNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/155—
Atrial fibrillationCardiac disorders3/155—
Myocardial infarctionCardiac disorders3/155—
Gastrointestinal haemorrhageGastrointestinal disorders3/155—
DeathGeneral disorders3/155—
Most frequent other events
Showing 10 of 12
Most frequent other events
EventImatinib Mesylate (On-Treatment)Imatinib Mesylate (Post-Treatment)
Blood creatinine increasedInvestigations17/155—
NauseaGastrointestinal disorders12/155—
AnaemiaBlood and lymphatic system disorders11/155—
DiarrhoeaGastrointestinal disorders11/155—
Back painMusculoskeletal and connective tissue disorders11/155—
MyalgiaMusculoskeletal and connective tissue disorders10/155—
COVID-19Infections and infestations9/155—
ArthralgiaMusculoskeletal and connective tissue disorders9/155—
Muscle spasmsMusculoskeletal and connective tissue disorders9/155—
Periorbital oedemaEye disorders8/155—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Imatinib Mesylate
Mean64.3 ± 13.07
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib Mesylate
Female63
Male92
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Imatinib Mesylate
08

Study locations

29 sites
  • University of California LA
    Los Angeles, California 90095, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Sidney Kimmel CCC At JH
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Weill Cornell Medical Center
    New York, New York 10021, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Uni Of TX MD Anderson Cancer Cntr
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Nanjing, Jiangsu 210002, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Novartis Investigative Site
    Shanghai, 200433, China
  • Novartis Investigative Site
    Helsinki, 00029, Finland
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Hong Kong, 999077, Hong Kong
  • Novartis Investigative Site
    Cluj-Napoca, Cluj 400015, Romania
  • Novartis Investigative Site
    Bucharest, 022328, Romania
  • Novartis Investigative Site
    Singapore, 119228, Singapore
  • Novartis Investigative Site
    Singapore, 168583, Singapore
  • Novartis Investigative Site
    Singapore, 169608, Singapore
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Ankara, Sihhiye Altindag 06230, Turkey (Türkiye)
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Manchester, M20 2BX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2013 to primary completion in Apr 2026, 156 months.

Results were first posted in Oct 2026, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2012
First posted
Dec 5, 2012
StartActual
Mar 26, 2013
Primary completionActual
Apr 20, 2026
CompletionActual
Apr 20, 2026
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Sites
1 site added, 1 site removed
Show site
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Show 1 removed
  • Novartis Investigative Site · Ankara, Turkey (Türkiye)
Oct 29, 2026
Primary outcomes
1 time frame changed, 1 removed, 1 description edited
What changed in the outcomes
  • RemovedFrequency and severity of Adverse Events (AEs) / Serious Adverse Events (SAEs)Time frame: Until no patients are left on study, with an expected average of 20 years
  • Time frameFrequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)From first dose of study treatment until 30 days after the last dose of study treatment, assessed up to approximately 13 years → From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)
  • DescriptionFrequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs): how it is measured was reworded
Oct 29, 2026
Documents
Secondary outcomes
1 time frame changed, 1 removed, 1 description edited
What changed in the outcomes
  • RemovedProportion of patients with clinical benefit as assessed by the investigatorTime frame: Until no patients are left on study, with an expected average of 20 years
  • Time frameProportion of Participants With Clinical Benefit as Assessed by the InvestigatorUp to approximately 13 years → Up to approximately 157 months
  • DescriptionProportion of Participants With Clinical Benefit as Assessed by the Investigator: how it is measured was reworded
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Novartis Investigative Site · Ankara, Turkey (Türkiye)
    Primary outcomes 1 time frame changed, 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedFrequency and severity of Adverse Events (AEs) / Serious Adverse Events (SAEs)Time frame: Until no patients are left on study, with an expected average of 20 years
    • Time frameFrequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)From first dose of study treatment until 30 days after the last dose of study treatment, assessed up to approximately 13 years → From first dose of study treatment through 30 days after the last dose of imatinib (up to approximately 157 months)
    • DescriptionFrequency and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs): how it is measured was reworded
    Secondary outcomes 1 time frame changed, 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedProportion of patients with clinical benefit as assessed by the investigatorTime frame: Until no patients are left on study, with an expected average of 20 years
    • Time frameProportion of Participants With Clinical Benefit as Assessed by the InvestigatorUp to approximately 13 years → Up to approximately 157 months
    • DescriptionProportion of Participants With Clinical Benefit as Assessed by the Investigator: how it is measured was reworded
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01742299
Responsible party
Sponsor
First posted
Dec 5, 2012
Start date
Mar 26, 2013
Primary completion
Apr 20, 2026
Completion
Apr 20, 2026
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion